[go: up one dir, main page]

ATE368122T1 - Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer - Google Patents

Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer

Info

Publication number
ATE368122T1
ATE368122T1 AT00926354T AT00926354T ATE368122T1 AT E368122 T1 ATE368122 T1 AT E368122T1 AT 00926354 T AT00926354 T AT 00926354T AT 00926354 T AT00926354 T AT 00926354T AT E368122 T1 ATE368122 T1 AT E368122T1
Authority
AT
Austria
Prior art keywords
lentiviral vectors
recombinant lentiviral
high titre
safe high
producing safe
Prior art date
Application number
AT00926354T
Other languages
English (en)
Inventor
Luigi Naldini
Thomas Dull
Anatoly Bukovsky
Deborah Farson
Rochelle Witt
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE368122T1 publication Critical patent/ATE368122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
AT00926354T 1999-04-29 2000-04-26 Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer ATE368122T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13167199P 1999-04-29 1999-04-29

Publications (1)

Publication Number Publication Date
ATE368122T1 true ATE368122T1 (de) 2007-08-15

Family

ID=22450511

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00926354T ATE368122T1 (de) 1999-04-29 2000-04-26 Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
AT07012545T ATE528406T1 (de) 1999-04-29 2000-04-26 Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07012545T ATE528406T1 (de) 1999-04-29 2000-04-26 Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer

Country Status (9)

Country Link
US (2) US7250299B1 (de)
EP (2) EP1849873B1 (de)
JP (1) JP4979851B2 (de)
AT (2) ATE368122T1 (de)
AU (1) AU778698B2 (de)
CA (1) CA2370103C (de)
DE (1) DE60035676T2 (de)
IL (1) IL146144A0 (de)
WO (1) WO2000066759A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1301214A2 (de) * 2000-05-26 2003-04-16 Chiron Corporation Verfahren zur transduktion von neuronalen zellen unter verwendung von lentivirusvektoren
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
JP2011500036A (ja) 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
DK2790737T3 (en) * 2011-12-12 2019-03-18 Childrens Hospital Philadelphia COMMERCIAL LARGE SCALE LENTIVIRUS VECTOR-MANUFACTURING SYSTEM AND VECTORS MADE THEREOF
JP2015520175A (ja) 2012-06-05 2015-07-16 ジ・オーストラリアン・ナショナル・ユニバーシティー インターロイキン−４アンタゴニストを伴うワクチン接種
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6467661B2 (ja) 2013-02-06 2019-02-13 セルジーン コーポレイション 改善された特異性を有する改変型ｔリンパ球
FI2956477T4 (fi) 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
EA037850B1 (ru) 2013-08-29 2021-05-27 Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Способы и композиции для рнк-направленного лечения вич-инфекции
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
WO2016007827A1 (en) 2014-07-11 2016-01-14 Anthrogenesis Corporation Methods of improving vector transduction efficiency into t lymphocytes
US20180080008A1 (en) 2014-08-12 2018-03-22 Anthrogenesis Corporation Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
SI3411478T1 (sl) 2016-02-01 2022-10-28 Bioverativ Therapeutics Inc. Optimirani geni dejavnika VIII
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
EP4092049A1 (de) 2016-10-20 2022-11-23 Celgene Corporation Cereblon-basierte heterodimerisierbare chimäre antigenrezeptoren
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
CN111918674A (zh) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 表达因子viii的慢病毒载体的用途
SG11202112344VA (en) 2019-05-23 2021-12-30 Massachusetts Inst Technology Ligand discovery and gene delivery via retroviral surface display
EP4038182A1 (de) 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentivirale vektorformulierungen
US20220403438A1 (en) 2019-10-08 2022-12-22 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
CA3212006A1 (en) 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN115247190B (zh) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
KR20240043780A (ko) 2021-08-06 2024-04-03 셀진 코포레이션 조작된 단백질의 선택적 분해를 위한 조성물 및 방법
EP4388008A1 (de) 2021-08-16 2024-06-26 Hemogenyx Pharmaceuticals Llc Anti-flt3-antikörper, car, car-t-zellen und verfahren zur verwendung
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
FR2629469B1 (fr) 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
AU6075190A (en) 1989-06-30 1991-01-17 Regents Of The University Of California, The Retrovirus detection
WO1993017118A2 (en) * 1992-02-28 1993-09-02 Syngenix Limited Defective packaging non-oncoviral vectors based on mpmv and hiv
US6051427A (en) 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995030755A1 (fr) * 1994-05-10 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997020052A1 (en) 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
US5750383A (en) * 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
EP0970201A1 (de) 1996-09-17 2000-01-12 The Salk Institute For Biological Studies Retrovirale vektoren, die sich nicht teilende zellen transduzieren können
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
CZ137399A3 (cs) * 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
EP1003894A2 (de) * 1997-07-18 2000-05-31 Chiron Corporation Lentivirale vektoren
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
PT1076715E (pt) * 1998-05-13 2007-10-26 Genetix Pharmaceuticals Inc Células empacotadoras lentivirais

Also Published As

Publication number Publication date
JP4979851B2 (ja) 2012-07-18
JP2003508017A (ja) 2003-03-04
AU4489700A (en) 2000-11-17
EP1849873A1 (de) 2007-10-31
EP1171624A1 (de) 2002-01-16
AU778698B2 (en) 2004-12-16
EP1171624B1 (de) 2007-07-25
DE60035676D1 (de) 2007-09-06
US20080241929A1 (en) 2008-10-02
US8652837B2 (en) 2014-02-18
IL146144A0 (en) 2002-07-25
CA2370103C (en) 2011-08-02
EP1171624A4 (de) 2002-06-26
EP1849873B1 (de) 2011-10-12
DE60035676T2 (de) 2008-04-30
CA2370103A1 (en) 2000-11-09
US7250299B1 (en) 2007-07-31
ATE528406T1 (de) 2011-10-15
WO2000066759A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
ATE368122T1 (de) Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
DE69838758D1 (de) Verfahren und mittel zur herstellung von sicheren, rekombinanten lentivirusvektoren mit hohem titer
DE3888885D1 (de) Halbleiteranordnung und verfahren zur herstellung.
DE3853220D1 (de) Verfahren und Gerät zur Herstellung von Produkten.
DE3765211D1 (de) Stabilisierter zirconocen/aluminoxan-katalysator und verfahren zur herstellung desselben.
DE3689195D1 (de) Verfahren zur Herstellung von Aloe-Erzeugnissen, Erzeugnisse und Zusammensetzungen dazu.
DE69406559D1 (de) Integriertes Verfahren zur Herstellung von Brenngas und Sauerstoff enthaltenden organischen Produkten
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE68907447D1 (de) Geblasene, einstueckige flasche und verfahren zur herstellung derselben.
DE69007639D1 (de) Silberkatalysator zur Produktion von Ethylenoxid und Verfahren zur Herstellung davon.
DE69702630D1 (de) Verfahren und Katalysator zur Herstellung von Distickstoffmonoxid
DE3871175D1 (de) Verfahren zur herstellung von perovskit und abo3-typ-oxyden.
ATE41668T1 (de) Verfahren und vorrichtung zur herstellung hochmolekularer polyester.
ATE71297T1 (de) Feste arzneizubereitungen mit dihydropyridin und verfahren zu ihrer herstellung.
DE59101232D1 (de) Verfahren und Mittel zur Herstellung von Bohrungen.
DE68916886D1 (de) Warmfestes Polyvinylchlorid-Copolymerisat und Verfahren zur Herstellung des Copolymerisats.
DE3668765D1 (de) Verfahren zur herstellung von borstenwaren und danach hergestellte borstenwaren.
DE3861709D1 (de) Anti-hiv-mittel und methode zu deren erzeugung.
ATA232687A (de) Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels
DE3761356D1 (de) Verfahren und extrusionsblasmaschine zur herstellung von flachflaschen.
DE3787543D1 (de) Verfahren zur herstellung von 6,13-dihydrochinacridonen und chinacridonen.
DE68909000D1 (de) Kornorientierte Siliziumstahlbleche mit niedrigen Wattverlusten und Verfahren zur Herstellung derselben.
DE68908464D1 (de) Nadelfoermige titandioxydteilchen und verfahren zu ihrer herstellung.
DE3774542D1 (de) Halbleiterlaser und verfahren zu seiner herstellung.
DE3873767D1 (de) Verfahren zur herstellung keramischer verbundwerkstoffe, enthaltend siliziumoxynitrid und zirkoniumoxid.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties